Sofosbuvir-Induced Erythrodermic Pityriasis Rubra Pilaris-Like Drug Eruption
Cheung, E.J.; Jedrych, J.J.; English, J.C.
Journal of Drugs in Dermatology Jdd 14(10): 1161-1162
2015
ISSN/ISBN: 1545-9616 PMID: 26461830 Document Number: 679100
Until 2011, the standard-of-care therapy for patients with hepatitis C consisted of interferon and ribavirin. The recent advent of new targeted therapies against this virus has provided more options of treatment for infected patients. Sofosbuvir, a nucleotide inhibitor of hepatitis C virus (HCV) RNA polymerase, was recently approved by the US Food and Drug Administration in 2013. Various Phase 3 trials with sofosbuvir combination therapy have reported an incidence of rash between 7% and 18%. We here describe a case of sofosbuvir-induced erythrodermic pityriasis rubra pilaris-like drug eruption.